Fresh analysis reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Published data in a prominent health publication points out that while obese individuals can lose about a fifth of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals using these treatments need to be informed of the potential of quick rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about 18 months.
Analyzing Approaches
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.
Scientists note that people who lose weight through diet and exercise typically see a less rapid creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts propose the mode of action of the injections accounts for the heightened weight return.
These medications imitate a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
The NHS suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, given the high risk of relapse, the therapy should be considered life-long.
This view is supported by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," akin to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a sudden resurgence of hunger.
"It felt as if a trigger that goes on and you're instantly starving," said an individual.
This challenge is compounded if users have not adopted sustainable dietary or behavioural changes during therapy.
Growing Use
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is greater among females than males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on combined lifestyle support.
